|
|
MDM2 |
MDM2 proto-oncogene |
- AKT phosphorylates targets in the cytosol
- Oxidative Stress Induced Senescence
- Oncogene Induced Senescence
- SUMOylation of transcription factors
- SUMOylation of ubiquitinylation proteins
- Trafficking of AMPA receptors
- Constitutive Signaling by AKT1 E17K in Cancer
- Ub-specific processing proteases
- Regulation of TP53 Activity through Phosphorylation
- Regulation of TP53 Degradation
- Regulation of TP53 Activity through Methylation
- Stabilization of p53
- Regulation of RUNX3 expression and activity
- Signaling by ALK fusions and activated point mutants
- Degradation of CDH1
- NPAS4 regulates expression of target genes
|
- Zinc
- Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
- Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
- Penile cancer
- Alveolar rhabdomyosarcoma
- Choriocarcinoma
- Osteosarcoma
- Glioma
|
|
|
MGMT |
O-6-methylguanine-DNA methyltransferase |
- MGMT-mediated DNA damage reversal
|
- Cysteine
- Zinc
- S-Methylcysteine
- S-Benzylcysteine
- Dinitrochlorobenzene
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
|
MS4A1 |
membrane spanning 4-domains A1 |
|
- Rituximab
- Ibritumomab tiuxetan
- Tositumomab
- Ofatumumab
- Obinutuzumab
- Technetium Tc-99m nofetumomab merpentan
- Ublituximab
- Ocrelizumab
- Mosunetuzumab
- Odronextamab
|
|
|
|
MYC |
MYC proto-oncogene, bHLH transcription factor |
- Transcription of E2F targets under negative control by DREAM complex
- Signaling by ALK
- NOTCH1 Intracellular Domain Regulates Transcription
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Binding of TCF/LEF:CTNNB1 to target gene promoters
- MAPK6/MAPK4 signaling
- Ub-specific processing proteases
- Interleukin-4 and Interleukin-13 signaling
- Cyclin E associated events during G1/S transition
- Cyclin A:Cdk2-associated events at S phase entry
- TFAP2 (AP-2) family regulates transcription of cell cycle factors
- RUNX3 regulates WNT signaling
- Estrogen-dependent gene expression
- Transcriptional regulation of granulopoiesis
- Regulation of CDH1 mRNA translation by microRNAs
- Regulation of NFE2L2 gene expression
- Regulation of PD-L1(CD274) transcription
|
- Acetylsalicylic acid
- Dimethyl sulfoxide
- Doconexent
- Nadroparin
|
- Penile cancer
- Breast cancer
- Laryngeal cancer
- Oral cancer
- Multiple myeloma
- Kaposi's sarcoma
- Ovarian cancer
- Choriocarcinoma
- Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
- Burkitt lymphoma
- Small cell lung cancer
- Osteosarcoma
- Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
|
|
|
MYCN |
MYCN proto-oncogene, bHLH transcription factor |
- Signaling by ALK
- Regulation of CDH1 mRNA translation by microRNAs
- TGFBR3 expression
- Regulation of PD-L1(CD274) transcription
|
|
- Neuroblastoma
- Feingold syndrome
|
|
|
MYF5 |
myogenic factor 5 |
- Myogenesis
- Myogenesis
- TGFBR3 expression
|
|
|
|
|
NAP1L4 |
nucleosome assembly protein 1 like 4 |
|
|
|
|
|
NCL |
nucleolin |
- Major pathway of rRNA processing in the nucleolus and cytosol
- Respiratory syncytial virus (RSV) attachment and entry
|
|
|
|
|
NR1D2 |
nuclear receptor subfamily 1 group D member 2 |
- Nuclear Receptor transcription pathway
|
|
|
|
|
P4HB |
prolyl 4-hydroxylase subunit beta |
- Collagen biosynthesis and modifying enzymes
- Insulin processing
- Detoxification of Reactive Oxygen Species
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- Hedgehog ligand biogenesis
- VLDL assembly
- Post-translational protein phosphorylation
- Chylomicron assembly
- LDL remodeling
- Interleukin-12 signaling
- Interleukin-23 signaling
|
- Zinc
- Ribostamycin
- Copper
- Artenimol
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
|
|
|
PAK1 |
p21 (RAC1) activated kinase 1 |
- Generation of second messenger molecules
- Regulation of actin dynamics for phagocytic cup formation
- FCERI mediated MAPK activation
- FCERI mediated MAPK activation
- CD28 dependent Vav1 pathway
- EPHB-mediated forward signaling
- Ephrin signaling
- Sema3A PAK dependent Axon repulsion
- Activation of RAC1
- Signal transduction by L1
- Smooth Muscle Contraction
- VEGFR2 mediated vascular permeability
- CD209 (DC-SIGN) signaling
- RHO GTPases activate PKNs
- RHO GTPases Activate ROCKs
- RHO GTPases activate PAKs
- RHO GTPases activate PAKs
- MAPK6/MAPK4 signaling
- G beta:gamma signalling through CDC42
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOQ GTPase cycle
- RHOH GTPase cycle
- RHOJ GTPase cycle
- RHOU GTPase cycle
- RAC3 GTPase cycle
- RHOV GTPase cycle
|
|
|
|
|
PICK1 |
protein interacting with PRKCA 1 |
- Cell surface interactions at the vascular wall
- Trafficking of GluR2-containing AMPA receptors
|
|
|
|
|
PIN1 |
peptidylprolyl cis/trans isomerase, NIMA-interacting 1 |
- ISG15 antiviral mechanism
- RHO GTPases Activate NADPH Oxidases
- Regulation of TP53 Activity through Phosphorylation
- PI5P Regulates TP53 Acetylation
- Negative regulators of DDX58/IFIH1 signaling
|
- Beta-(2-Naphthyl)-Alanine
- 3,6,9,12,15,18-HEXAOXAICOSANE
|
|
|
|
PIN4 |
peptidylprolyl cis/trans isomerase, NIMA-interacting 4 |
|
|
|
|
|
PPP1R1B |
protein phosphatase 1 regulatory inhibitor subunit 1B |
- DARPP-32 events
- DARPP-32 events
|
|
|
|
|
PPP1R2 |
protein phosphatase 1 regulatory inhibitor subunit 2 |
|
|
|
|
|
PPP1R8 |
protein phosphatase 1 regulatory subunit 8 |
- mRNA Splicing - Major Pathway
|
|
|
|
|
PRNP |
prion protein (Kanno blood group) |
- NCAM1 interactions
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
|
|
- Prion diseases; Creutzfeldt-Jacob disease (CJD); Gerstmann-Straussler disease (GSD); Gerstmann-Straussler-Scheinker disease (GSSD); Fatal familial insomnia (FFI)
|
|
|
PTEN |
phosphatase and tensin homolog |
- Synthesis of PIPs at the plasma membrane
- Synthesis of IP3 and IP4 in the cytosol
- Negative regulation of the PI3K/AKT network
- Downstream TCR signaling
- TP53 Regulates Metabolic Genes
- PTEN Loss of Function in Cancer
- Ub-specific processing proteases
- Ovarian tumor domain proteases
- Regulation of PTEN mRNA translation
- Regulation of PTEN localization
- Regulation of PTEN stability and activity
- Transcriptional Regulation by MECP2
|
|
- Vulvar cancer
- Breast cancer
- Malignant melanoma
- Prostate cancer
- Hepatocellular carcinoma
- Small cell lung cancer
- Endometrial Cancer
- Glioma
|
|
|
PTPN1 |
protein tyrosine phosphatase non-receptor type 1 |
- Integrin signaling
- Negative regulation of MET activity
- Insulin receptor recycling
- Regulation of IFNG signaling
- PTK6 Down-Regulation
- MECP2 regulates neuronal receptors and channels
- Regulation of IFNA/IFNB signaling
- Growth hormone receptor signaling
- Growth hormone receptor signaling
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
|
- 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid
- 2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid
- 5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid
- 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid
- 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide
- [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,
- {4-[(2S)-2-({[(1S)-1-Carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid
- Compound 19
- 3-(4-{2-[2-(2-bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid
- 2-(Oxalyl-Amino)-Benzoic Acid
- {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)
- Novo Nordisk a/S Compound
- N-(Bromoacetyl)-beta-alanyl-N-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-L-serinamide
- 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
- PNU177836
- 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
- {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid
- 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide
- (4S)-5-[[(2S)-1-[[(2S)-1-Amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid
- 4-[[(2S)-1-[[6-[(1-Amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid
- L-cysteic acid
- 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid
- -Carbonyl]-Amino}-Butyric Acid
- Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid
- 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid
- 2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid
- 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide
- [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid
- {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid
- N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide
- 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID
- ISIS 113715
- Trodusquemine
- Ertiprotafib
- 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID
- [(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid
- 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID
- 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
- 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID
- [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid
- 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID
- 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID
- 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID
- 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN
- N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE
- [(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid
- 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE
- 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID
- ISOTHIAZOLIDINONE ANALOG
- 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid
- p-Benzoyl-L-phenylalanine
- 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID
- (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER
- 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
- 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE
- (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid
|
|